Funding profile · Autoimmune drug discovery

Ditto Biosciences

A preclinical parasite protein company with four named investors, roughly $500,000 on the record, and no filing of any kind at the SEC. The databases that track it do not agree on what the round was.

$500KTotal raised to date, per PitchBook and Tracxn
4Named investors on record (PitchBook)
0SEC filings of any form, EDGAR searched Sep 24, 2026
$0Federal grant dollars found (NIH, NSF)

Data as of September 24, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Jan 1, 2026 Accelerator, Y Combinator Winter 2026 Not disclosed Y Combinator PitchBook
Jan 1, 2026 Seed, as recorded by Tracxn $500,000 total to date 1 institutional investor, unnamed in the free record Tracxn
Mar 16, 2026 Seed Not disclosed Pioneer Fund, named by Preqin PitchBook, Preqin
Mar 20, 2026 Portfolio announcement Not disclosed Multimodal Ventures Investor post
Q2 2026 Listed as a new investment Not disclosed Flex Capital Investor letter
Undated Pre-Seed, as labeled by a portfolio tracker $500K Pioneer Fund VCBacked
To date Federal non dilutive funding $0 None found at NIH or NSF Public record

What the filings show

SEC EDGAR · no filing found · searched Sep 24, 2026

Company search
No registrant named Ditto Bio or Ditto Biosciences
Full text search
0 hits for Ditto Bio, 0 for Ditto Biosciences, 0 for dittobio.com
Form D
None on file
Investment vehicles
No SPV or fund series named for the company
What that means
Either no Regulation D offering has been made, or the money came in under Section 4(a)(2), which requires no Form D
Filing
SEC EDGAR, no CIK assigned

Reading the filings

  1. The whole record is one number.PitchBook and Tracxn both put the total raised at $500,000. PitchBook splits it across two events, an accelerator deal dated January 1, 2026 and a seed round dated March 16, 2026. Tracxn records a single seed round on January 1, 2026. Neither breaks the amount out by event, so $500,000 is the ceiling on everything that has closed, not the size of a priced round.
  2. Four investors, one total.PitchBook names Flex Capital, Multimodal Ventures, Pioneer Fund and Y Combinator. Spread evenly across four, $500,000 is $125,000 each. That arithmetic is an upper bound rather than a fact: the accelerator deal is logged separately, and no source allocates the money.
  3. The databases disagree on the label.Tracxn calls it Seed. PitchBook calls one deal Accelerator and the other Seed. VCBacked labels it Pre-Seed. Preqin records one completed deal, most recent March 16, 2026, with Pioneer Fund. All four are describing the same $500,000.
  4. The investors disclosed before the trackers did.Multimodal announced the investment on March 20, 2026, four days after the seed date PitchBook and Preqin carry. Flex Capital listed Ditto Bio among six new investments in a Q2 2026 letter. Neither named an amount, and no press release exists.
  5. Nothing is non dilutive.No NIH or NSF award is on record. For a preclinical biotech that is a live gap: federal grants are the usual bridge between a seed and a first candidate, and the company is carrying none.
  6. One database narrative is unsupported.Preqin describes a revenue model built on licensing and joint ventures and says the company plans to expand into Europe and Asia by the end of 2026. No company statement, investor post or company blog says either of those things.

Commercial signals

Signal Detail Source type
Regulatory No FDA record, no registered clinical trial, no investigational new drug application, no named candidate. Not found
Product MoleculeMapper, a computational platform. One published analysis, Mar 2, 2026, mapping about 10,000 viral proteins to human targets. Company-stated
Revenue None reported. The launch post asks immunologists, biologics developers and protein designers to make contact, which points to partnering. Company-stated
Customers or partners None named. Not found
Headcount 3 on the Y Combinator profile. 5 per Tracxn as of Jul 31, 2026, and 5 per PitchBook. Databases
Programs and advisors California Life Sciences FAST Fall 2026 cohort. Pitched at the DeepMind startup sessions at Google. Advisors named as Russell Vance, Liang Schweizer and Jonathan Asfaha. Company-stated
Registered address San Francisco per Y Combinator, Tracxn and Preqin. PitchBook lists 815 Solano Avenue, Albany, CA. Sources differ

What to watch

  • A Form D. One is due within 15 days of the first sale in any Regulation D offering, so a filing would settle both the amount and the date.
  • A priced seed or Series A large enough to fund wet lab work, which is where the current $500,000 runs out fast.
  • A first grant application landing at NIH or NSF.
  • A pharma partnership or option deal, which for a platform at this stage is the realistic path to revenue.
  • Whether the two addresses resolve to one registered office.

The Ditto Biosciences story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • CellType: Shared investor: Independent Pioneer Fund. A two person Yale spinout that translates single cell biology into a language large models can learn, and is using that model to steer a real cancer drug's next act
  • Ligo Biosciences: Shared investor: Multimodal Ventures. A San Francisco startup building generative diffusion models to design enzymes from scratch
  • Lamar Health: Shared investor: Flex Capital. A San Francisco startup that builds AI software to automate the referral, benefits verification and prior authorization paperwork behind expensive specialty drugs
  • Parallel Bio: Also in Drug Discovery and Delivery. Miniature human lymph nodes, grown from donated tissue and run side by side across hundreds of donors, used to test drugs and vaccines before anyone takes them

Sources

  1. Public recordSEC EDGAR company and full text search, no resultsSEC · Sep 24, 2026
  2. Public recordNIH and NSF award searches, no award to the companyNIH, NSF · Sep 24, 2026
  3. IndependentCompany profile, deals and investorsPitchBook · Sep 2026
  4. IndependentCompany profile, funding and headcountTracxn · Sep 2026
  5. IndependentDitto Biosciences asset profilePreqin · Sep 2026
  6. IndependentPioneer Fund therapeutics portfolio listingVCBacked · Sep 2026
  7. IndependentFlex Capital Q2 2026 highlightsFlex Capital · Jul 2, 2026
  8. InvestorDitto Bio joins the Multimodal Ventures portfolioLinkedIn · Mar 2026
  9. CompanyLaunch YC: Ditto Bio, evolutionary therapies for autoimmune diseaseY Combinator · Feb 2026
  10. CompanyMapping parasite molecules to treat autoimmune diseaseDitto Bio blog · Mar 2, 2026
  11. CompanyLinkedIn page: advisors, FAST cohort, DeepMind pitchLinkedIn · 2026

Compiled from SEC, NIH, NSF and other public records and published reports as of September 24, 2026. Form D notices report offerings under Regulation D; no such notice has been filed by this company, and companies that raise under Section 4(a)(2) file none. Healthcare Venture Capital Fund holds no position in Ditto Biosciences. This page is not an offer to sell or a recommendation to buy any security.